May 17th 2024
Tarlatamab — now with the brand name Imdelltra — is the first approved bispecific antibody for a solid tumor.
Keytruda Receives Full Approval as First-Line Treatment in Bladder Cancer
September 1st 2021The approval follows the FDA’s Oncologic Drugs Advisory Committee voting 5-3 in favor of maintaining the approval despite a confirmatory trial that found Keytruda did not meet the end points of overall survival and progression-free survival.